ROCO
6586
Market cap178mUSD
Nov 13, Last price
30.40TWD
Name
CHO Pharma Inc
Chart & Performance
P/E
—
P/S
1,562.41
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.18%
Rev. gr., 5y
64.52%
Revenues
4m
Net income
-212m
L-30.66%
CFO
-217m
L-25.33%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CHO Pharma, Inc., a biopharmaceutical company, develops and commercializes therapeutic and diagnostic products for the unmet clinical needs. It is developing homogeneous antibody drugs, such as CHO-H01, CHO-H02, and CHO-A04, a humanized monoclonal antibody for cancer; CHO-H03, a homogeneous antibody drug for autoimmune diseases; CHO-S05 dual-effect anti-flu drugs; and CHO-V08 for Klebsiella pneumonia. The company was founded in 2012 and is based in Taipei City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||